From the Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Baylor College of Medicine; and Ben Taub General Hospital, Harris County Hospital District, Houston, Texas.
Obstet Gynecol. 2011 Jan;117(1):119-124. doi: 10.1097/AOG.0b013e3182029180.
To estimate the rate of wound complications associated with protocol-driven postcesarean enoxaparin thromboprophylaxis.
After implementing an Institutional Clinical Practice Guideline for postoperative cesarean delivery thromboprophylaxis among at-risk gravid women (older than 35 years of age, body mass index greater than 30 kg/m2, or both), data on all cesarean deliveries over the first 23 months of guideline implementation were extracted and analyzed. Primary (wound hematoma, separation, or dehiscence) and secondary (venous thromboembolism) outcomes were compared in stratified and multivariable models controlling for potential confounders.
Over 23 months, 2,509 cesarean deliveries were performed. A total of 1,677 (68%) gravid women met criteria for thromboprophylaxis; 653 received enoxaparin per protocol ("cases"), and, at the discretion of the ordering physician, 1,024 did not (at-risk, protocol-noncompliant "controls"). Cases differed significantly by virtue of maternal age, body mass index, and diabetic status. Univariable analysis subsequently revealed a higher rate of wound separation (6.8% compared with 3.6%, P=.003), rehospitalization (2.1% compared with 0.8%, P=.017) and composite score (8.9% compared with 4.8%, P=.002) among protocol-compliant cases, but no increased risk of wound hematoma (P>.06). In multivariable analysis, adjusted odds ratios continued to reveal an association between enoxaparin use and wound separation (OR 1.66, P=.04) as well as higher composite score (OR 1.69, P=.01). However, among the protocol-noncompliant controls, a nonsignificant increase in the rate of venous thromboembolism occurred.
In our series, prophylactic enoxaparin use among at-risk gravid women undergoing cesarean delivery was accompanied by an increased risk of wound separation.
II.
评估与协议驱动的剖宫产术后依诺肝素血栓预防相关的伤口并发症发生率。
在实施一项针对高危孕妇(年龄大于 35 岁、体重指数大于 30kg/m2 或两者兼有的)剖宫产术后血栓预防的机构临床实践指南后,提取并分析了指南实施头 23 个月内所有剖宫产的数据。在分层和多变量模型中,控制潜在混杂因素后,比较了主要(伤口血肿、分离或裂开)和次要(静脉血栓栓塞)结局。
在 23 个月内,进行了 2509 次剖宫产。共有 1677 名(68%)孕妇符合血栓预防标准;653 名孕妇按方案接受依诺肝素治疗(“病例”),而根据医嘱,1024 名孕妇未接受(高危、方案不合规“对照”)。病例在产妇年龄、体重指数和糖尿病状况方面存在显著差异。单变量分析随后显示,在符合方案的病例中,伤口分离(6.8%比 3.6%,P=.003)、再住院(2.1%比 0.8%,P=.017)和复合评分(8.9%比 4.8%,P=.002)的发生率更高,但伤口血肿的风险无增加(P>.06)。多变量分析中,调整后的优势比继续显示依诺肝素使用与伤口分离(比值比 1.66,P=.04)以及更高的复合评分(比值比 1.69,P=.01)之间存在关联。然而,在方案不合规的对照组中,静脉血栓栓塞的发生率出现了无统计学意义的增加。
在我们的系列研究中,高危孕妇行剖宫产时预防性使用依诺肝素与伤口分离风险增加相关。
II。